On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.

Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.

The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.

Confirmed Case

On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.

Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.

it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.

What Is Ebola Virus Disease?

As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.

How Does Transmission Work?

Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.

It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.

It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.

Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.

Symptoms:

• feeling tired
• headache
• muscle and joint pain
• eye pain and vision problems
• weight gain
• belly pain and loss of appetite
• hair loss and skin problems
• trouble sleeping
• memory loss
• hearing loss
• depression and anxiety

A powerful synthetic opioid that is described to be up to 10 times stronger than fentanyl is spreading through the US illicit drug supply, raising concerns about a new and deadly driver of overdoses.

According to a drug threat notice from the White House Office of National Drug Control Policy (ONDCP), the drug, cychlorphine, has now been detected in every region of the United States, . It was particularly prevalent in Ohio, Texas and Tennessee.

At least 55 deaths were linked to cychlorphine in 2025 and 2026, according to the federal warning. Tennessee has recorded the largest number of confirmed deaths so far. The number of drug samples containing the opioid also increased sharply, from just one in 2024 to 106 samples from 10 states in 2025.

All About Cychlorphine

Cychlorphine is a synthetic opioid, meaning it is manufactured chemically rather than derived directly from the opium poppy.

Belonging to a growing group of highly potent synthetic opioids, cychlorphine has crept up in the illicit drug supply in the US in the last few years. ONDCP says that cychlorphine could be “up to ten times more potent than fentanyl”.

Fentanyl is already notorious for being an extremely powerful opioid. Cychlorphine adds another layer of risk to an illicit drug supply that is already difficult to predict.

Fentanyl is an incredibly powerful opioid. The CDC says illegally manufactured fentanyl is about 50 times stronger than heroin and 100 times stronger than morphine. Cychlorphine may be up to 10 times more potent than fentanyl, according to the ONDCP.

That level of potency means the difference between an amount that produces an opioid effect and an amount that causes a fatal overdose can be extremely small.

Also read: 21% In 80 Weeks: Lancet Study Finds Lilly’s Retatrutide Delivers One Of The Biggest Weight Losses Ever

Cychlorphine Is Hard To Detect

Cychlorphine can be mixed into other drugs or pressed into counterfeit prescription pills, meaning someone may believe they are taking a familiar medication when the tablet actually contains a much more powerful opioid.

Powerful synthetic opioids can be mixed into other drugs or pressed into counterfeit pills. The DEA has similarly warned that nitazenes, another class of potent synthetic opioids, are being mixed with fentanyl, heroin and counterfeit prescription pills.

Fentanyl test strips do not detect cychlorphine, so a negative fentanyl test does not mean a drug is free from cychlorphine. "Cychlorphine is not detected by drug test strips or in routine hospital opioid urine screens," ONDCP warned.

This also means that deaths from the drug are likely being underestimated, according to the Journal of Pain Research. The author, Robert Raffa, professor emeritus at Temple University's School of Pharmacy in Philadelphia, confirmed the drug is detected in a specialized lab.

ONDCP Warns

The New York Times reported that multiple doses of Narcan may be needed to reverse cychlorphine's effects, while people responding to an overdose may have only one or two doses available.

ONDCP has warned that anyone who might respond to an overdose should be ready with extra doses of naloxone (Narcan), a drug that helps reverse opioid overdoses. But response to these extremely potent synthetic opioids can be complicated.

34-year-old ABC News correspondent Will Reeve, the son of late actor Christopher Reeve, recently revealed his testicular cancer diagnosis. He said that first noticed a tender lump that seemed like nothing but it turned out to be the first sign of cancer.

Reeve recently opened up about his diagnosis and treatment journey, revealing that he first noticed something unusual in his left testicle while showering in April. He initially thought it would go away.

“I assumed it was nothing or would go away,” He told People.

But his wife, Amanda Dubin Reeve, encouraged him to get it checked. He got an ultrasound and found out later that it was a mass. “It’s probably nothing,” she told him, “but what if it’s something?”

Reeve's story highlights the importance of catching signs of testicular cancer. Any change that seems minor should not automatically be dismissed, particularly if it persists.

Will Reeve's Testicular Cancer Diagnosis

After the ultrasound showed a mass, Reeve underwent surgery to remove the affected testicle, a procedure called an orchiectomy.

Testing showed that most of his cancer was embryonal carcinoma, an aggressive type of testicular cancer. Doctors subsequently found cancer in three lymph nodes in his abdomen, leading to another surgery and two rounds of chemotherapy.

“I hadn’t had surgery since I got my tonsils out at 5,” said Reeve. “So I was more nervous about the unknown of the surgery rather than the overwhelming realization that I would be losing an essential part of my body forever.”

He took a few days off work to recover and was declared cancer-free on September 8.

Also read: H. pylori, HPV Among Five Infections Behind 1 In 8 Cancers Worldwide: Lancet

Early Signs Of Testicular Cancer

A lump on the testicle is one of the most common first signs of testicular cancer. The lump may or may not always be painful. Other possible changes include:

• Swelling or enlargement of a testicle
• A feeling of heaviness in the scrotum
• An ache or discomfort in the testicle or lower abdomen
• A change in the size or consistency of a testicle
• Breast enlargement or tenderness in some cases

The American Cancer Society notes that many of these symptoms can also be caused by other conditions that are not cancer, including infections or injuries. However, any unexplained lump or persistent change should be evaluated by a doctor.

This is one reason a new lump can be easy to overlook. Most testicular cancers do not cause pain, although some tumours can cause aching or discomfort. In Reeve's case, the lump was tender, but he initially assumed it was nothing serious.

Also read: IARC Says Low-Dose CT Can Cut Lung Cancer Deaths: AIIMS Expert Explains Why India Needs Its Own Screening Evidence

Who Is At Risk?

Testicular cancer is generally uncommon overall, but it is the most common cancer in young men, particularly those in their teens and 20s.

Certain factors can increase risk, including having had an undescended testicle, a previous testicular tumour or a family history of testicular cancer.

If you notice a lump or a tender swelling on your testicles, get evaluated by a medical professional immediately.

A doctor can examine the testicle and may recommend an ultrasound, which can help determine whether a mass is present and whether further evaluation is needed.

Before jumping to conclusions, remember that conditions like infections, fluid accumulation or enlarged veins can also cause swelling or changes in the testicle. But the only way to know what is causing the new change is to get it checked.

Amid rising demand for surgical care, the US is expected to face a significant shortage of surgeons by 2038, according to the first unified assessment of the country’s surgical workforce.

The study, presented at the American College of Surgeons (ACS) Clinical Congress 2026, projects that the US will face a shortfall of 27,940 surgeons nationally.

This comes as demand for surgeons is projected to increase by 12.8%, while the overall surgeon workforce is expected to decline by 4.2% between 2023 and 2038. The workforce would meet just 84.3% of projected national need.

“Studies usually look at one specialty at a time, so a shortage looks like that specialty’s problem,” said lead author Fernando Ribeiro Duraes, a medical student at Case Western Reserve University School of Medicine.

“When you put all 10 specialties together, you can see supply is projected to fall while demand keeps rising, and that the gaps are worse in rural areas. The fixes have to be targeted by specialty and by geography, not incremental.”

Which Specialties Will Face The Biggest Shortages?

Researchers used the Health Workforce Simulation Model (HWSM), a federal model from the US Department of Health and Human Services, to analyze surgeon supply and demand across 10 surgical specialties from 2023 to 2038.

The analysis found that overall surgeon supply is projected to decline 4.2% from 2023 to 2038, while demand is expected to rise 12.8%.

The specialties projected to face the most critical shortages include:

• Vascular surgery — 65.8% of need met
• Ophthalmology — 71.8%
• Thoracic surgery — 73.1%
• Plastic surgery — 74.1%
• Urology — 84.4%
• Otolaryngology — 87.5%
• Orthopedics — 87.9%
• Neurosurgery — 88.7%

Only general surgery, at 91.3% and colorectal surgery, at 98.3%, are projected to remain close to meeting demand.

At the same time, the gaps between surgeon supply and demand are also projected to be greater in rural areas.

What Could This Mean For Patients?

For patients, surgical shortages could mean longer waits for procedures.

Patients may also need to travel farther for medical care, particularly in rural areas where some people may have to drive hours to access treatment.

The researchers said the findings point to the need for targeted workforce policies and geography-focused strategies rather than incremental changes.

Duraes pointed to a proposed bill, H.R. 3890, the Resident Physician Shortage Reduction Act, as one potential response.

The bill would increase the number of residency positions, which the ACS says has not changed since 1997. It also proposes addressing federal student loan limits and expanding loan-forgiveness programmes to encourage physicians to practise in rural areas.

“The fixes have to be targeted by specialty and by geography” if they are expected to work, Duraes said.

Global Health Workforce Crisis

The US shortage projection comes amid broader concerns about health workforce shortages worldwide.

Nearly one in four doctors globally is older than 55 and could retire within the next decade, according to the World Health Organization’s National Health Workforce Accounts: Health Workforce Levels and Trends 2026.

The report, the first in an annual series providing a global picture of health workforce levels and trends, said ageing among health workers is intensifying shortages in some countries, while population ageing is simultaneously increasing demand for healthcare services.

The global health worker shortage has fallen from 20 million in 2013 to 15 million in 2020. However, newer analysis has revised the projected shortage for 2030 upward to 11.1 million, compared with an earlier estimate of about 10 million.